A phase 1b clinical trial of the CD40-activating antibody CP-870,893 in combination with cisplatin and pemetrexed in malignant pleural mesothelioma

A Phase I Study of an Agonist CD40 Monoclonal Antibody (CP-870,893) in Combination with Gemcitabine in Patients with Advanced Pancreatic Ductal Adenocarcinoma

(2013) G. L. Beatty et al.   CLINICAL CANCER RESEARCH

B-cell biology and development

(2013) Kathrin Pieper et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells

(2013) Paul F Robbins et al.   NATURE MEDICINE

Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors

(2013) Robert H. Vonderheide et al.   OncoImmunology

A Phase II Study of Intermittent Sunitinib Malate as Second-Line Therapy in Progressive Malignant Pleural Mesothelioma

(2012) Anna K. Nowak et al.   Journal of Thoracic Oncology

Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors

(2011) Jens Rüter et al.   CANCER BIOLOGY & THERAPY

Activation of human B cells by the agonist CD40 antibody CP-870,893 and augmentation with simultaneous toll-like receptor 9 stimulation

(2009) Erica L Carpenter et al.   Journal of Translational Medicine